$PBIO NetworkNewsBreaks - Pressure BioSciences In
Post# of 106707
(Total Views: 174)
Posted On: 07/09/2019 9:13:00 AM
$PBIO NetworkNewsBreaks - Pressure BioSciences Inc.'s (PBIO) PCT Platform Highlighted at Spectrometry Conference
Published: July 8, 2019 3:10 p.m. ET
Jul 08, 2019 (NetworkNewsWire via COMTEX) -- Pressure BioSciences (otcqb
BIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences industry, recently announced that its patented pressure cycling technology ("PCT"
platform was featured in 15 independent scientific presentations at the annual conference of the American Society of Mass Spectrometry ("ASMS" (http://nnw.fm/geA6Y). An article further discussing the company reads, "The ASMS annual meeting is a highly reputable conference attended by more than 10,000 scientists from around the world. It is a showcase event for new research and scientific findings that has been held every year since 1953. . . . This year's PCT-involving presentations spanned a range of applications -- from cancer research to molecular biology and biomarker discovery. Of the 15 presentations, nine focused on the importance of PBIO's PCT platform in cancer research. Three of these presentations put emphasis on the use of streamlined sample preparation protocols and systems featuring Pressure BioSciences' Barocycler 2320EXT instrument and its associated and proprietary MicroTubes."
To view the full article, visit: http://nnw.fm/Z30uh
About Pressure BioSciences Inc.
Pressure BioSciences (otcqb BIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company's products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT" hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). PBIO's primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST" platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company's website at www.PressureBiosciences.com.
https://www.marketwatch.com/press-release/net...quote_news
Published: July 8, 2019 3:10 p.m. ET
Jul 08, 2019 (NetworkNewsWire via COMTEX) -- Pressure BioSciences (otcqb
BIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences industry, recently announced that its patented pressure cycling technology ("PCT" platform was featured in 15 independent scientific presentations at the annual conference of the American Society of Mass Spectrometry ("ASMS" (http://nnw.fm/geA6Y). An article further discussing the company reads, "The ASMS annual meeting is a highly reputable conference attended by more than 10,000 scientists from around the world. It is a showcase event for new research and scientific findings that has been held every year since 1953. . . . This year's PCT-involving presentations spanned a range of applications -- from cancer research to molecular biology and biomarker discovery. Of the 15 presentations, nine focused on the importance of PBIO's PCT platform in cancer research. Three of these presentations put emphasis on the use of streamlined sample preparation protocols and systems featuring Pressure BioSciences' Barocycler 2320EXT instrument and its associated and proprietary MicroTubes." To view the full article, visit: http://nnw.fm/Z30uh
About Pressure BioSciences Inc.
Pressure BioSciences (otcqb
BIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company's products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT" hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). PBIO's primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST" platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company's website at www.PressureBiosciences.com. https://www.marketwatch.com/press-release/net...quote_news
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!